Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
NCT01377935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113505
Last updated 2016-09-20
Summary
The purpose of this study is to compare the incidence of hospitalization for acute kidney injury among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of other oral antidiabetic drugs in classes other than Dipeptidyl peptidase IV (DPP4) inhibitors.
Conditions
- Diabetes Mellitus, Type 2
Sponsors & Collaborators
- collaborator INDUSTRY
- collaborator OTHER
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
More Related Trials
-
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
NCT03508739 ·Status: SUSPENDED ·Phase: PHASE3
-
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
NCT03550378 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Mechanism of Action/Splay vs. TmG
NCT00726505 ·Status: TERMINATED ·Phase: PHASE1
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
NCT06094231 ·Status: TERMINATED ·Phase: NA
-
Use of Sitagliptin to Decrease Microalbuminuria
NCT02048904 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
NCT01948986 ·Status: COMPLETED ·Phase: PHASE1
-
Decision Impact Trial of KidneyIntelX
NCT04791358 ·Status: RECRUITING
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
NCT03795389 ·Status: COMPLETED ·Phase: PHASE1
-
Dapagliflozin Treatment in Type 2 Diabetes
NCT04620590 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
NCT01135446 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT01847092 ·Status: COMPLETED ·Phase: PHASE2
-
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT03315143 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
NCT03557658 ·Status: COMPLETED ·Phase: PHASE1
-
OPTIMISE-CKD Drug Utilization
NCT05932901 ·Status: COMPLETED
-
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NCT02010242 ·Status: COMPLETED ·Phase: PHASE2
-
SGLT2 Inhibition in Hemodialysis
NCT05179668 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
NCT01621178 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966 ·Status: COMPLETED ·Phase: PHASE4
-
Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
NCT05713851 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
NCT02796170 ·Status: COMPLETED ·Phase: PHASE4
-
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372 ·Status: TERMINATED ·Phase: PHASE2